How to Check If You Have an STD: What to Expect

Getting tested for a sexually transmitted infection typically involves a urine sample, a swab, a blood draw, or some combination of the three, depending on which infections you’re being screened for and where on the body they might be. The whole process is faster and less invasive than most people expect, and knowing what each step involves makes it far less intimidating. What often surprises people more than the testing itself is how many STIs produce no symptoms at all, which means the only reliable way to know your status is to get tested.

Most STIs Do Not Announce Themselves

One of the strongest reasons to get tested is that the majority of STI cases are completely silent. In one study, researchers estimated that about 77% of chlamydia cases and 45% of gonorrhea cases never produced any symptoms.¹ A retrospective review of nearly 640 people screened at a South African clinic found that roughly 37% tested positive for an STI, and of those, only about 12% had any signs or symptoms at all. Nearly 89% of chlamydia infections and 82% of gonorrhea infections in that group were asymptomatic.² These aren’t fringe numbers. Cross-sectional surveys of military populations have found asymptomatic chlamydia prevalence ranging from about 3% to 7% depending on the group.³

The takeaway is straightforward: waiting for symptoms before getting tested means you could carry and pass along an infection for months or years without knowing it. Routine screening catches what your body does not flag.

Urine Samples and Swabs for Chlamydia, Gonorrhea, and Trichomoniasis

For the most commonly screened bacterial and parasitic STIs, the test itself is simple. You’ll either pee into a cup or a clinician will take a swab, sometimes both. If you’re a woman, a vaginal swab is the most sensitive option. A meta-analysis comparing the two approaches found that vaginal swabs detected chlamydia with about 94% sensitivity compared to roughly 87% for urine, with similar gaps for gonorrhea and trichomoniasis.⁴ That doesn’t mean urine testing is bad. It’s still quite accurate, and many clinics use it because it’s easier and less uncomfortable.

For men, both urethral swabs and urine samples work well with modern molecular testing. Older studies found that swab specimens had slightly higher sensitivity than urine for detecting chlamydia in men (about 96% versus 93%) and gonorrhea (100% versus 95%).⁵ In practice, most clinics now rely on urine for men because the difference is small and patients strongly prefer it.

If a clinician hands you a cup, there’s one important detail: you’ll be asked to provide a “first-catch” urine sample. That means the first portion of urine you produce, not a midstream sample like you’d give for a urinalysis. The initial stream is more likely to carry bacteria from the urethra, which is exactly what the test is looking for.

When the Throat and Rectum Need Testing Too

Standard urine and genital swab tests miss infections in the throat and rectum. If you’ve had oral or anal sex, infections at those sites can go completely undetected by a genital-only screening. Extragenital sites act as hidden reservoirs for chlamydia and gonorrhea and play a meaningful role in ongoing transmission.⁶ You can have a throat or rectal infection without having a genital one at the same time, which means genital screening alone could come back clean while you’re still carrying and potentially spreading the infection.

The testing procedure is a quick swab of the throat or rectum. Molecular tests used for these sites are the same type used for genital specimens, though additional research is ongoing to fully characterize their performance at extragenital locations.⁷ The discomfort is minimal and brief. If your clinician doesn’t ask about your sexual practices, bring it up yourself so they know which sites to test.

Blood Tests for HIV, Syphilis, and Herpes

Some infections can only be diagnosed through a blood draw. HIV testing looks for antibodies your immune system produces in response to the virus, and newer tests also detect a viral protein called p24 antigen. Syphilis screening similarly relies on antibody detection. Herpes blood tests look for antibodies to HSV-1 and HSV-2.

Herpes blood testing, though, comes with a significant accuracy problem. In a study of 278 patients with confirmed HSV-2 infection by PCR, only about 38% tested positive on the HSV-2 IgG antibody test.⁸ That’s a lot of missed infections. Herpes blood tests also produce false positives, particularly in populations where the infection is uncommon. This is why most guidelines do not recommend routine herpes blood testing in people without symptoms. If you have sores or an active outbreak, a direct swab of the lesion using PCR testing is far more reliable.

Syphilis testing is more straightforward but still imperfect. Clinical diagnosis by visual inspection alone has been shown to over-diagnose syphilis, with a positive predictive value of only about 50% in one assessment of STD clinics.⁹ Blood-based antibody tests perform much better and are the standard for syphilis screening.

Window Periods and When to Test

Every STI test has a window period: the gap between when you’re exposed and when the test can reliably detect the infection. Testing too soon after an exposure can produce a false negative, giving you a clean result when you’re actually infected.

HIV has the most thoroughly studied window period. Modern laboratory tests that detect both antigen and antibody can reliably pick up infection with a median window of about 18 days after exposure. The 99th percentile of the window period for these combination tests is roughly 44 days, meaning nearly everyone who is infected will test positive within about six weeks. Older-generation tests take longer; the Western blot, for instance, had a median window of around 37 days and a 99th percentile out to 65 days.¹⁰ If you had a specific exposure that concerns you, most guidelines suggest testing at the two-to-four-week mark and again at 45 days or later to be sure.

For chlamydia and gonorrhea, molecular tests can typically detect infection within one to two weeks of exposure. Syphilis antibodies usually appear within three to six weeks. The key point is that a negative test taken three days after a concerning encounter is essentially meaningless for most STIs. If you’re told “we need you to come back,” it’s not because the clinic is being cautious for its own sake. It’s because the biology of the infection requires time before the test can work.

What a Lesion Swab Involves

If you have a visible sore, blister, or ulcer, a clinician will likely swab it directly. This is the gold standard for diagnosing active herpes outbreaks and primary syphilis lesions. Multiplex PCR assays, which test for several pathogens from a single swab, have proven highly accurate. One study found that PCR was more sensitive than standard diagnostic methods for detecting HSV, syphilis, and chancroid from genital ulcers, with sensitivities of 100%, 91%, and 98%, respectively, compared to 72%, 81%, and 74% for traditional testing.¹¹

An evaluation of multiplex PCR for syphilis-suspected lesions found that 44.6% of samples tested positive for the syphilis bacterium and 21% for herpes, with about 5% showing coinfections.¹² The practical lesson is that what looks like one thing may actually be another, and sometimes it’s both. A clinician’s visual impression is a starting point, not a diagnosis. The swab provides the answer.

Self-Collected Samples and At-Home Kits

If visiting a clinic feels like a barrier, at-home STI test kits let you collect your own specimens and mail them to a lab. The accuracy is reassuring. A systematic review and meta-analysis found that self-collected specimens performed comparably to clinician-collected specimens for diagnosing most STIs in women.¹³ For chlamydia specifically, self-collected vaginal swabs had a pooled sensitivity of about 92% compared to clinician-collected cervical swabs.¹⁴

For men, self-collected penile swabs have also shown strong performance. In one study comparing self-collected penile-meatal swabs to clinician-collected urethral swabs, there were no significant differences in accuracy for chlamydia, gonorrhea, trichomoniasis, or mycoplasma.¹⁵ At-home kits generally include clear instructions and pre-labeled containers. You collect the sample, seal it, and ship it. Results typically come back within a few days.

The main limitation is coverage. Most mail-in kits test for a handful of common infections and may not include everything a full clinic panel would. They’re a strong option for routine screening of chlamydia, gonorrhea, HIV, and syphilis, but less suited for situations where you need a physical exam or a direct lesion swab.

Rapid Tests and Same-Day Results

Rapid point-of-care tests can give you an answer in minutes rather than days. For syphilis, rapid tests perform well, with sensitivity consistently above 90% in evaluations.¹⁶ Rapid HIV tests are similarly reliable and widely available.

For chlamydia and gonorrhea, though, the picture is more complicated. Rapid tests that rely on older antigen-detection technology have pooled sensitivity of only about 56% for chlamydia, meaning they miss nearly half of infections. Newer molecular-based rapid tests perform much better, with pooled sensitivity around 94%.¹⁷ The challenge is that the better molecular rapid tests are not yet widely available in many clinical settings, and there are currently no rapid tests capable of detecting antibiotic resistance in gonorrhea.¹⁸

If a clinic offers you a rapid test and the result is negative but you have reason to believe you were exposed, it’s reasonable to request a standard lab-based test for confirmation. A rapid negative is only as good as the test’s sensitivity allows.

Making Sense of Your Results

A positive result on a well-validated molecular test is generally reliable, and your clinician will proceed with treatment. But results aren’t always straightforward, especially in certain contexts. When a test has even a small false-positive rate, the math can work against you in populations where the infection is uncommon. As one analysis demonstrated, a test with 97% specificity applied to a group where only 3% actually have the infection yields a positive predictive value of just 50%, meaning half of the positive results would be wrong.¹⁹

This is most relevant for herpes blood testing and for screening in low-risk populations. It’s less of an issue for chlamydia and gonorrhea molecular tests, which have specificities close to 100%. If your result seems inconsistent with your risk profile, a confirmatory test using a different method is the standard next step. A negative result, meanwhile, only reflects your status at the time of the test minus the window period. It doesn’t guarantee you weren’t recently infected.

Cost, Insurance, and Where to Go

Cost is one of the biggest practical barriers to STI testing. Research has found that patients who face out-of-pocket costs of $30 or more are significantly less likely to return for recommended repeat screening for chlamydia and gonorrhea.²⁰ Even among insured patients visiting STD clinics, roughly a third identified copays or deductibles as a barrier to using their insurance for STI care.²¹

In the United States, publicly funded STD clinics, Planned Parenthood locations, and community health centers often offer testing on a sliding-fee scale based on income, and some provide free testing for specific infections. Under the Affordable Care Act, most private insurance plans are required to cover recommended preventive STI screenings without cost-sharing, though what counts as “recommended” depends on your age, sex, and risk factors. If you’re unsure, calling ahead to ask about pricing avoids surprises.

Confidentiality and Minors

Privacy concerns keep many people from getting tested, especially younger people. Most states allow minors to consent to STI testing without parental involvement, and research suggests these laws may make a real difference in testing rates. A study of over 46,000 high school students found that male adolescents were significantly more likely to report having tested for HIV in states that explicitly allowed minors to consent to testing, did not permit parental notification, or had confidentiality protections for insured dependents.²²

For adults, STI results are part of your medical record but are protected under standard health-privacy laws. STD clinics in particular tend to have strong confidentiality practices because their patients depend on discretion. One practical concern for younger adults on a parent’s insurance plan is that an explanation-of-benefits statement might reveal the visit. If that’s a worry, going to a clinic that offers free or sliding-scale services and paying out of pocket keeps the visit off the insurance record entirely.

Stigma as a Barrier

The evidence consistently shows that stigma is one of the most powerful deterrents to getting tested. Among adolescents, perceiving higher levels of STD-related stigma was independently associated with lower odds of having been tested in the past year.²³ College students delay or avoid testing even when services are readily available, with social stigma and fear of negative consequences identified as significant barriers.²⁴ A qualitative study in New Zealand identified three intertwined categories of barriers: personal factors like underestimating risk and embarrassment, structural factors like cost and clinician attitudes, and social factors centered on the fear of being judged.²⁵

The reality is that STI testing is one of the most routine things that happens in a clinic. Healthcare providers do this constantly. Nobody is surprised or judgmental. If the thought of walking into a clinic feels overwhelming, at-home kits remove the social element almost entirely.

Telling Partners and Expedited Treatment

If you test positive, notifying sexual partners is an important step that many people dread but that has real public-health value. In some cases, clinicians can provide what’s called expedited partner therapy, where medication or a prescription is given to you to pass along to a partner so they can be treated without a separate clinic visit. Trials and program evaluations of expedited partner therapy generally show increased rates of partner treatment, though only some demonstrate clear reductions in reinfection.²⁶

Pilot programs have tested different models for partner notification in primary care, including pharmacy-based treatment options and dedicated hotlines. In one trial, between 35% and 46% of contactable partners were treated within six weeks of the original diagnosis across various approaches.²⁷ The numbers are sobering: even with active outreach, a majority of partners go untreated. That said, any partner treated is one fewer link in the chain of transmission, and most health departments offer anonymous notification services if you’re not comfortable having the conversation yourself.

Why Antibiotic Resistance Matters for Your Gonorrhea Test

Gonorrhea has developed resistance to nearly every class of antibiotic used against it over the decades, and this has practical implications for how you’re tested and treated. Emerging resistance threatens to undermine the effectiveness of current therapy and prevention strategies.²⁸ Current first-line treatment relies on injectable ceftriaxone, and researchers are developing molecular tests that could identify resistance patterns from the same swab used for diagnosis. One study found that such assays could help spare ceftriaxone use in susceptible cases, though the approach requires careful attention to changing resistance patterns over time.²⁹

For you as a patient, the practical upshot is that if you’re treated for gonorrhea, your clinician may recommend a follow-up test a week or two later to confirm the antibiotic actually worked. This “test of cure” is becoming more common precisely because treatment failure, while still uncommon, is no longer unheard of. It also means that gonorrhea is one infection where treating yourself with leftover antibiotics is particularly risky, since the wrong antibiotic or the wrong dose can contribute to further resistance without clearing the infection.